AMED Quote, Financials, Valuation and Earnings

Health Catalyst has a net margin of 10.26% compared to Amedisys's net margin of -25.97%. Amedisys's return on equity of 7.55% beat Health Catalyst's return on equity of -19.29%.

Amedisys has a consensus price target of $96.86, signalling upside risk potential of 0.78%. On the other hand Health Catalyst has an analysts' consensus of $8.23 which suggests that it could grow by 102.14%. Given that Health Catalyst has higher upside potential than Amedisys, analysts believe Health Catalyst is more attractive than Amedisys.

Amedisys has a beta of 0.964, which suggesting that the stock is 3.612% less volatile than S&P 500. In comparison Health Catalyst has a beta of 1.559, suggesting its more volatile than the S&P 500 by 55.873%.

Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Health Catalyst offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amedisys pays -- of its earnings as a dividend. Health Catalyst pays out -- of its earnings as a dividend.

Amedisys quarterly revenues are $594.8M, which are larger than Health Catalyst quarterly revenues of $79.6M. Amedisys's net income of $61M is higher than Health Catalyst's net income of -$20.7M. Notably, Amedisys's price-to-earnings ratio is 35.46x while Health Catalyst's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.34x versus 0.80x for Health Catalyst. Usually stocks with elevated PS ratios are considered overvalued.

Humana has a net margin of 10.26% compared to Amedisys's net margin of 3.87%. Amedisys's return on equity of 7.55% beat Humana's return on equity of 10.08%.

Amedisys has a consensus price target of $96.86, signalling upside risk potential of 0.78%. On the other hand Humana has an analysts' consensus of $309.40 which suggests that it could grow by 22.89%. Given that Humana has higher upside potential than Amedisys, analysts believe Humana is more attractive than Amedisys.

Amedisys has a beta of 0.964, which suggesting that the stock is 3.612% less volatile than S&P 500. In comparison Humana has a beta of 0.494, suggesting its less volatile than the S&P 500 by 50.63%.

Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humana offers a yield of 1.41% to investors and pays a quarterly dividend of $0.89 per share. Amedisys pays -- of its earnings as a dividend. Humana pays out 35.71% of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amedisys quarterly revenues are $594.8M, which are smaller than Humana quarterly revenues of $32.1B. Amedisys's net income of $61M is lower than Humana's net income of $1.2B. Notably, Amedisys's price-to-earnings ratio is 35.46x while Humana's PE ratio is 17.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.34x versus 0.25x for Humana. Usually stocks with elevated PS ratios are considered overvalued.

Option Care Health has a net margin of 10.26% compared to Amedisys's net margin of 3.51%. Amedisys's return on equity of 7.55% beat Option Care Health's return on equity of 15.22%.

Amedisys has a consensus price target of $96.86, signalling upside risk potential of 0.78%. On the other hand Option Care Health has an analysts' consensus of $38.56 which suggests that it could grow by 17.76%. Given that Option Care Health has higher upside potential than Amedisys, analysts believe Option Care Health is more attractive than Amedisys.

Amedisys has a beta of 0.964, which suggesting that the stock is 3.612% less volatile than S&P 500. In comparison Option Care Health has a beta of 0.763, suggesting its less volatile than the S&P 500 by 23.686%.

Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amedisys pays -- of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend.

Amedisys quarterly revenues are $594.8M, which are smaller than Option Care Health quarterly revenues of $1.3B. Amedisys's net income of $61M is higher than Option Care Health's net income of $46.7M. Notably, Amedisys's price-to-earnings ratio is 35.46x while Option Care Health's PE ratio is 26.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.34x versus 1.08x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

OptimizeRx has a net margin of 10.26% compared to Amedisys's net margin of -0.24%. Amedisys's return on equity of 7.55% beat OptimizeRx's return on equity of -16.71%.

Amedisys has a consensus price target of $96.86, signalling upside risk potential of 0.78%. On the other hand OptimizeRx has an analysts' consensus of $10.83 which suggests that it could grow by 16.11%. Given that OptimizeRx has higher upside potential than Amedisys, analysts believe OptimizeRx is more attractive than Amedisys.

Amedisys has a beta of 0.964, which suggesting that the stock is 3.612% less volatile than S&P 500. In comparison OptimizeRx has a beta of 1.283, suggesting its more volatile than the S&P 500 by 28.349%.

Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OptimizeRx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amedisys pays -- of its earnings as a dividend. OptimizeRx pays out -- of its earnings as a dividend.

Amedisys quarterly revenues are $594.8M, which are larger than OptimizeRx quarterly revenues of $32.3M. Amedisys's net income of $61M is higher than OptimizeRx's net income of -$78K. Notably, Amedisys's price-to-earnings ratio is 35.46x while OptimizeRx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.34x versus 1.85x for OptimizeRx. Usually stocks with elevated PS ratios are considered overvalued.